Literature DB >> 19797070

Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhimurium.

Christina Berchtold1, Klaus Panthel, Stefan Jellbauer, Brigitte Köhn, Elisabeth Roider, Miriam Partilla, Jürgen Heesemann, Stefan Endres, Carole Bourquin, Holger Rüssmann.   

Abstract

Preexisting antivector immunity can severely compromise the ability of Salmonella enterica serovar Typhimurium live vaccines to induce protective CD8 T-cell frequencies after type III secretion system-mediated heterologous protein translocation in orally immunized mice. To circumvent this problem, we injected CpG DNA admixed to the immunodominant p60(217-225) peptide from Listeria monocytogenes subcutaneously into BALB/c mice and coadministered a p60-translocating Salmonella strain by the orogastric route. The distribution of tetramer-positive p60(217-225)-specific effector and memory CD8 T cells was analyzed by costaining of lymphocytes with CD62L and CD127. In contrast to the single oral application of recombinant Salmonella or single immunization with CpG and p60, in the spleens from mice immunized with a combination of both vaccine types a significantly higher level of p60-specific CD8 T cells with a predominance of the effector memory T-cell subset was detected. In vivo protection studies revealed that this CD8 T-cell population conferred sterile protective immunity against a lethal infection with L. monocytogenes. However, p60-specific central memory CD8 T cells induced by single vaccination with CpG and p60 were not able confer effective protection against rapidly replicating intracellular Listeria. In conclusion, we provide compelling evidence that the combination of Salmonella type III-mediated antigen delivery and CpG immunization is an attractive novel vaccination strategy to modulate CD8 differentiation patterns toward distinct antigen-specific T-cell subsets with favorable protective capacities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19797070      PMCID: PMC2786444          DOI: 10.1128/IAI.00700-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

Review 2.  Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA.

Authors:  A M Krieg; H Wagner
Journal:  Immunol Today       Date:  2000-10

Review 3.  Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.

Authors:  D M Klinman; S Kamstrup; D Verthelyi; I Gursel; K J Ishii; F Takeshita; M Gursel
Journal:  Springer Semin Immunopathol       Date:  2000

4.  A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets.

Authors:  Christian Stemberger; Katharina M Huster; Martina Koffler; Florian Anderl; Matthias Schiemann; Hermann Wagner; Dirk H Busch
Journal:  Immunity       Date:  2007-12       Impact factor: 31.745

Review 5.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 6.  Origin of CD8+ effector and memory T cell subsets.

Authors:  Christian Stemberger; Michael Neuenhahn; Veit R Buchholz; Dirk H Busch
Journal:  Cell Mol Immunol       Date:  2007-12       Impact factor: 11.530

7.  Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.

Authors:  E Davila; E Celis
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

Review 8.  Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors.

Authors:  Klaus Panthel; Katrin M Meinel; Victòria E Sevil Domènech; Konrad Trülzsch; Holger Rüssmann
Journal:  Int J Med Microbiol       Date:  2007-08-23       Impact factor: 3.473

9.  Pre-existing anti-Salmonella vector immunity prevents the development of protective antigen-specific CD8 T-cell frequencies against murine listeriosis.

Authors:  Victòria E Sevil Domènech; Klaus Panthel; Katrin M Meinel; Sebastian E Winter; Holger Rüssmann
Journal:  Microbes Infect       Date:  2007-08-07       Impact factor: 2.700

10.  Heterologous prime-boost immunizations with different Salmonella serovars for enhanced antigen-specific CD8 T-cell induction.

Authors:  Victòria E Sevil Domènech; Klaus Panthel; Sebastian E Winter; Holger Rüssmann
Journal:  Vaccine       Date:  2008-02-14       Impact factor: 3.641

View more
  4 in total

1.  Assessment of the phenotype and functionality of porcine CD8 T cell responses following vaccination with live attenuated classical swine fever virus (CSFV) and virulent CSFV challenge.

Authors:  Giulia Franzoni; Nitin V Kurkure; Daniel S Edgar; Helen E Everett; Wilhelm Gerner; Kikki B Bodman-Smith; Helen R Crooke; Simon P Graham
Journal:  Clin Vaccine Immunol       Date:  2013-08-21

2.  CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma.

Authors:  Stefan Jellbauer; Klaus Panthel; Justin H Hetrodt; Holger Rüssmann
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

Review 3.  Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis.

Authors:  Jose Rey-Ladino; Allen G P Ross; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1.

Authors:  Heather Friberg; Luis J Martinez; Leyi Lin; Jason M Blaylock; Rafael A De La Barrera; Alan L Rothman; J Robert Putnak; Kenneth H Eckels; Stephen J Thomas; Richard G Jarman; Jeffrey R Currier
Journal:  mSphere       Date:  2020-01-22       Impact factor: 4.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.